Novo Nordisk Begins Study of Lexicon Oral Obesity Drug
By Nicholas G. Miller
Novo Nordisk began a Phase 1 study of an oral obesity-drug candidate it agreed to license from Lexicon Pharmaceuticals last year.
The study is investigating the safety and tolerability of the drug, called LX9851, how it moves through the body and its physiological and biological impacts as compared with placebo in 96 people with overweight or obesity. The trial is expected to be completed in the first quarter of 2027.
Lexicon has earned a second $10 million milestone payment in 2026 from Novo Nordisk following initial dosing requirements in the study. The company is also eligible for a third $10 million milestone payment that could be achieved later this year.
In total, Lexicon is eligible to receive up to $1 billion in upfront and potential development, regulatory and sales milestone payments. It is also entitled to tiered royalties on net sales of LX9851.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
March 23, 2026 08:20 ET (12:20 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
The 10 Best Companies to Invest in Now
2 Undervalued Stocks to Buy Before They Rebound
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
United States